GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (NAS:CLDX) » Definitions » E10

Celldex Therapeutics (Celldex Therapeutics) E10 : $-12.22 (As of Dec. 2023)


View and export this data going back to 1990. Start your Free Trial

What is Celldex Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Celldex Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.840. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-12.22 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 7.00% per year. During the past 5 years, the average E10 Growth Rate was 6.00% per year. During the past 10 years, the average E10 Growth Rate was 24.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Celldex Therapeutics was 48.00% per year. The lowest was -15.00% per year. And the median was 7.25% per year.

As of today (2024-04-30), Celldex Therapeutics's current stock price is $37.45. Celldex Therapeutics's E10 for the quarter that ended in Dec. 2023 was $-12.22. Celldex Therapeutics's Shiller PE Ratio of today is .


Celldex Therapeutics E10 Historical Data

The historical data trend for Celldex Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics E10 Chart

Celldex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.90 -15.17 -14.31 -13.50 -12.22

Celldex Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.50 -13.33 -13.07 -12.70 -12.22

Competitive Comparison of Celldex Therapeutics's E10

For the Biotechnology subindustry, Celldex Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celldex Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's Shiller PE Ratio falls into.



Celldex Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Celldex Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.84/129.4194*129.4194
=-0.840

Current CPI (Dec. 2023) = 129.4194.

Celldex Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201403 -4.950 99.695 -6.426
201406 -4.800 100.560 -6.178
201409 -4.650 100.428 -5.992
201412 -5.400 99.070 -7.054
201503 -4.950 99.621 -6.431
201506 -4.950 100.684 -6.363
201509 -4.800 100.392 -6.188
201512 -4.950 99.792 -6.420
201603 -5.250 100.470 -6.763
201606 -4.800 101.688 -6.109
201609 -4.350 101.861 -5.527
201612 -4.500 101.863 -5.717
201703 -4.200 102.862 -5.284
201706 -3.450 103.349 -4.320
201709 -3.000 104.136 -3.728
201712 -0.210 104.011 -0.261
201803 -12.610 105.290 -15.500
201806 -1.670 106.317 -2.033
201809 -0.660 106.507 -0.802
201812 -0.810 105.998 -0.989
201903 -1.400 107.251 -1.689
201906 -0.840 108.070 -1.006
201909 -0.750 108.329 -0.896
201912 -0.640 108.420 -0.764
202003 -0.730 108.902 -0.868
202006 -0.500 108.767 -0.595
202009 -0.360 109.815 -0.424
202012 -0.550 109.897 -0.648
202103 -0.420 111.754 -0.486
202106 -0.340 114.631 -0.384
202109 -0.450 115.734 -0.503
202112 -0.430 117.630 -0.473
202203 -0.490 121.301 -0.523
202206 -0.770 125.017 -0.797
202209 -0.570 125.227 -0.589
202212 -0.560 125.222 -0.579
202303 -0.620 127.348 -0.630
202306 -0.650 128.729 -0.653
202309 -0.810 129.860 -0.807
202312 -0.840 129.419 -0.840

Add all the adjusted EPS together and divide 10 will get our e10.


Celldex Therapeutics  (NAS:CLDX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Celldex Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Celldex Therapeutics (Celldex Therapeutics) Business Description

Traded in Other Exchanges
Address
53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
Executives
Garry Arthur Neil director 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Tibor Keler officer: Sen. VP & Ch Scientific Off. 30 PARK ROAD, OTTSVILLE PA 18942
Sarah Cavanaugh officer: SVP of Corp. Affairs & Admin. C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Diane C. Young officer: SVP, Chief Medical Officer 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Anthony S Marucci director, officer: President and CEO 66 COLD HILL DRIVE, MENDAHM NJ 07945
Richard M. Wright officer: Sr. VP & CCO C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Samuel Bates Martin officer: SVP and CFO C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Margo Heath-chiozzi officer: SVP of of Regulatory Affairs C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Elizabeth Crowley officer: SVP, Chief Product Dev Officer C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Freddy A. Jimenez officer: SVP & General Counsel C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
James J Marino director C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Keith L Brownlie director 777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Gerald Phd Mcmahon director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114